| scholarly article | Q13442814 |
| P50 | author | Guillermo Docena | Q61971894 |
| P2093 | author name string | Thomas T MacDonald | |
| Renata Curciarello | |||
| P2860 | cites work | Fibrocytes in health and disease | Q83371739 |
| Impaired IL-17 signaling pathway contributes to the increased collagen expression in scleroderma fibroblasts | Q83611830 | ||
| IL-33 attenuates development and perpetuation of chronic intestinal inflammation | Q83905314 | ||
| Mucosal expression of basic fibroblastic growth factor, syndecan 1 and tumour necrosis factor-α in Crohn's disease in deep remission under treatment with anti-TNFα antibodies | Q85651685 | ||
| Sesame oil accelerates healing of 2,4,6-trinitrobenzenesulfonic acid-induced acute colitis by attenuating inflammation and fibrosis | Q85656912 | ||
| Vitamin D prevents the intestinal fibrosis via induction of vitamin D receptor and inhibition of transforming growth factor-beta1/Smad3 pathway | Q85823706 | ||
| Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn's disease | Q86952010 | ||
| Decreased Fibrogenesis After Treatment with Pirfenidone in a Newly Developed Mouse Model of Intestinal Fibrosis | Q87234725 | ||
| Irsogladine maleate ameliorates inflammation and fibrosis in mice with chronic colitis induced by dextran sulfate sodium | Q87354202 | ||
| TGF-beta signal transduction | Q22003891 | ||
| Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls | Q24550675 | ||
| Endothelial to Mesenchymal Transition (EndoMT) in the Pathogenesis of Human Fibrotic Diseases | Q26748338 | ||
| Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey | Q26991848 | ||
| Molecular mechanisms of epithelial-mesenchymal transition | Q27013743 | ||
| Molecular mechanism of action of anti-tumor necrosis factor antibodies in inflammatory bowel diseases | Q28067245 | ||
| Infliximab maintenance therapy for fistulizing Crohn's disease | Q28246982 | ||
| IL-13 signaling through the IL-13alpha2 receptor is involved in induction of TGF-beta1 production and fibrosis | Q28285105 | ||
| Immunological and inflammatory functions of the interleukin-1 family | Q29619669 | ||
| IBD-associated TL1A gene (TNFSF15) haplotypes determine increased expression of TL1A protein | Q33415016 | ||
| Fate tracing reveals the pericyte and not epithelial origin of myofibroblasts in kidney fibrosis | Q33556248 | ||
| Mechanisms that mediate the development of fibrosis in patients with Crohn's disease | Q33754181 | ||
| Mechanisms of smooth muscle responses to inflammation | Q33797551 | ||
| Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial | Q34275637 | ||
| Inflammatory bowel disease-associated interleukin-33 is preferentially expressed in ulceration-associated myofibroblasts. | Q34358060 | ||
| Inhibition of a novel fibrogenic factor Tl1a reverses established colonic fibrosis | Q34381832 | ||
| LIGHT is constitutively expressed on T and NK cells in the human gut and can be induced by CD2-mediated signaling | Q34382093 | ||
| Macrophages in Tissue Repair, Regeneration, and Fibrosis | Q34518415 | ||
| IL-13 promotes collagen accumulation in Crohn's disease fibrosis by down-regulation of fibroblast MMP synthesis: a role for innate lymphoid cells? | Q34540573 | ||
| IL-33 promotes ST2-dependent lung fibrosis by the induction of alternatively activated macrophages and innate lymphoid cells in mice | Q34647885 | ||
| The aryl hydrocarbon receptor ligand ITE inhibits TGFβ1-induced human myofibroblast differentiation | Q34805707 | ||
| Differential regulation of interleukin 17 and interferon gamma production in inflammatory bowel disease | Q35001872 | ||
| Novel cytokine signaling pathways in inflammatory bowel disease: insight into the dichotomous functions of IL-33 during chronic intestinal inflammation | Q35191071 | ||
| Noncanonical STAT3 activation regulates excess TGF-β1 and collagen I expression in muscle of stricturing Crohn's disease | Q35205442 | ||
| Hallmarks of epithelial to mesenchymal transition are detectable in Crohn's disease associated intestinal fibrosis | Q35261897 | ||
| Inflammation-induced endothelial-to-mesenchymal transition: a novel mechanism of intestinal fibrosis | Q35474247 | ||
| Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis | Q35558781 | ||
| Interleukin-17A promotes the formation of inflammation in the lung tissues of rats with pulmonary fibrosis | Q35871239 | ||
| T helper 2 (Th2) cell differentiation, type 2 innate lymphoid cell (ILC2) development and regulation of interleukin-4 (IL-4) and IL-13 production | Q35940715 | ||
| Constitutive TL1A expression under colitogenic conditions modulates the severity and location of gut mucosal inflammation and induces fibrostenosis | Q35951975 | ||
| Secukinumab failure in Crohn's disease: the yeast connection? | Q45370364 | ||
| IL-13 signaling via IL-13R alpha2 induces major downstream fibrogenic factors mediating fibrosis in chronic TNBS colitis | Q46306807 | ||
| Identification of an atypical monocyte and committed progenitor involved in fibrosis | Q48014663 | ||
| Involvement of interleukin-17A-induced expression of heat shock protein 47 in intestinal fibrosis in Crohn's disease. | Q48331564 | ||
| Transcriptional regulation of inflammatory mediators secreted by human colonic circular smooth muscle cells. | Q51593449 | ||
| Transforming growth factor beta signalling and matrix metalloproteinases in the mucosa overlying Crohn's disease strictures. | Q51833572 | ||
| Aryl hydrocarbon receptor-driven signals inhibit collagen synthesis in the gut. | Q53203362 | ||
| Anti-fibrotic effects of a novel small compound on the regulation of cytokine production in a mouse model of colorectal fibrosis. | Q53264815 | ||
| Interleukin-13 damages intestinal mucosa via TWEAK and Fn14 in mice-a pathway associated with ulcerative colitis. | Q54350603 | ||
| Interleukin-33 expression is specifically enhanced in inflamed mucosa of ulcerative colitis. | Q54431742 | ||
| Smooth Muscle Hyperplasia/Hypertrophy is the Most Prominent Histological Change in Crohn's Fibrostenosing Bowel Strictures: A Semiquantitative Analysis by Using a Novel Histological Grading Scheme | Q57103773 | ||
| Implication of TNF-Related Apoptosis-Inducing Ligand in Inflammatory Intestinal Epithelial Lesions | Q59387489 | ||
| Regulation of IL-11 expression in intestinal myofibroblasts: role of c-Jun AP-1- and MAPK-dependent pathways | Q64377693 | ||
| [Transforming growth factor-beta signaling and cancer] | Q73486711 | ||
| Integration of Smad and MAPK pathways: a link and a linker revisited | Q75216840 | ||
| Interleukin-1beta and tumor necrosis factor-alpha induce chemokine and matrix metalloproteinase gene expression in human colonic subepithelial myofibroblasts | Q77827337 | ||
| Increased adhesion molecule expression in serosal fibroblasts isolated from patients with inflammatory bowel disease is secondary to inflammation | Q77847318 | ||
| Transforming growth factor-betas and their signaling receptors are coexpressed in Crohn's disease | Q77922697 | ||
| Interleukin (IL)-4 and IL-17 synergistically stimulate IL-6 secretion in human colonic myofibroblasts | Q78355142 | ||
| Reduced migration of fibroblasts in inflammatory bowel disease: role of inflammatory mediators and focal adhesion kinase | Q79249628 | ||
| Clinical course in Crohn's disease: results of a Norwegian population-based ten-year follow-up study | Q80135540 | ||
| Induction of IL-13 triggers TGF-beta1-dependent tissue fibrosis in chronic 2,4,6-trinitrobenzene sulfonic acid colitis | Q80178424 | ||
| Functional modulation of Crohn's disease myofibroblasts by anti-tumor necrosis factor antibodies | Q80611351 | ||
| Apoptosis in the intestinal mucosa of patients with inflammatory bowel disease: evidence of altered expression of FasL and perforin cytotoxic pathways | Q80903631 | ||
| Inflammatory responses induced by interleukin-17 family members in human colonic subepithelial myofibroblasts | Q81312230 | ||
| Characterization of the novel ST2/IL-33 system in patients with inflammatory bowel disease | Q82257596 | ||
| IL-33 induces IL-13-dependent cutaneous fibrosis | Q82370239 | ||
| Cellular origins of fibroblasts: possible implications for organ fibrosis in systemic sclerosis | Q35971144 | ||
| Eosinophils and IL-33 Perpetuate Chronic Inflammation and Fibrosis in a Pediatric Population with Stricturing Crohn's Ileitis | Q36053010 | ||
| Resveratrol has antiinflammatory and antifibrotic effects in the peptidoglycan-polysaccharide rat model of Crohn's disease. | Q36206802 | ||
| The TNF-family cytokine TL1A drives IL-13-dependent small intestinal inflammation | Q36219538 | ||
| Novel PPARγ Modulator GED-0507-34 Levo Ameliorates Inflammation-driven Intestinal Fibrosis | Q36479876 | ||
| IL-33-induced alterations in murine intestinal function and cytokine responses are MyD88, STAT6, and IL-13 dependent | Q36593464 | ||
| The aryl hydrocarbon receptor, more than a xenobiotic-interacting protein. | Q36782397 | ||
| Anti-melanin-concentrating hormone treatment attenuates chronic experimental colitis and fibrosis. | Q36837922 | ||
| Impact of patient characteristics on the clinical efficacy of mongersen (GED-0301), an oral Smad7 antisense oligonucleotide, in active Crohn's disease. | Q36847655 | ||
| The role of IL-33 in gut mucosal inflammation. | Q36914110 | ||
| Cytokine-induced chromatin modifications of the type I collagen alpha 2 gene during intestinal endothelial-to-mesenchymal transition | Q36933830 | ||
| Enhanced protection from fibrosis and inflammation in the combined absence of IL-13 and IFN-γ | Q37026406 | ||
| The role of interleukin 17 in Crohn's disease-associated intestinal fibrosis | Q37070931 | ||
| Effect of infliximab on small bowel stenoses in patients with Crohn's disease | Q37237678 | ||
| Neutralisation of the interleukin-33/ST2 pathway ameliorates experimental colitis through enhancement of mucosal healing in mice | Q37345931 | ||
| The interleukin-1 receptor/Toll-like receptor superfamily: 10 years of progress. | Q37374914 | ||
| Increased activation of latent TGF-β1 by αVβ3 in human Crohn's disease and fibrosis in TNBS colitis can be prevented by cilengitide | Q37469875 | ||
| Antagonism of Interleukin-17A ameliorates experimental hepatic fibrosis by restoring the IL-10/STAT3-suppressed autophagy in hepatocytes. | Q37706081 | ||
| Type 2 cytokines: mechanisms and therapeutic strategies | Q38424752 | ||
| Granulomatous enterocolitis induced in rats by purified bacterial cell wall fragments. | Q38591373 | ||
| Smad7 and its Potential as Therapeutic Target in Inflammatory Bowel Diseases | Q38664474 | ||
| Oral pirfenidone protects against fibrosis by inhibiting fibroblast proliferation and TGF-β signaling in a murine colitis model | Q38753378 | ||
| Proinflammatory cytokines induce crosstalk between colonic epithelial cells and subepithelial myofibroblasts: implication in intestinal fibrosis. | Q39349863 | ||
| TACE inhibition amplifies TNF-alpha-mediated colonic epithelial barrier disruption | Q39905192 | ||
| Snail1-induced partial epithelial-to-mesenchymal transition drives renal fibrosis in mice and can be targeted to reverse established disease | Q40666383 | ||
| TL1A as a Potential Local Inducer of IL17A Expression in Colon Mucosa of Inflammatory Bowel Disease Patients | Q40837206 | ||
| Absence of a role for interleukin-13 in inflammatory bowel disease | Q42236791 | ||
| Corticosteroids repress the interleukin 1 beta-induced secretion of collagenase in human intestinal smooth muscle cells | Q42447976 | ||
| Transforming growth factor-beta promotes pro-fibrotic behavior by serosal fibroblasts via PKC and ERK1/2 mitogen activated protein kinase cell signaling | Q42487388 | ||
| Targeting TGF-beta1 by employing a vaccine ameliorates fibrosis in a mouse model of chronic colitis | Q43238854 | ||
| IL-17 stimulates inflammatory responses via NF-kappaB and MAP kinase pathways in human colonic myofibroblasts | Q43997188 | ||
| Anti-tumor necrosis factor α prevents bowel fibrosis assessed by messenger RNA, histology, and magnetization transfer MRI in rats with Crohn's disease | Q44132897 | ||
| Development of Fibrosis in Acute and Longstanding Ulcerative Colitis | Q44206690 | ||
| Long-term evolution of disease behavior of Crohn's disease | Q44444450 | ||
| Tralokinumab for moderate-to-severe UC: a randomised, double-blind, placebo-controlled, phase IIa study | Q44696806 | ||
| A murine model of chronic inflammation-induced intestinal fibrosis down-regulated by antisense NF-kappa B. | Q44729219 | ||
| Anrukinzumab, an anti-interleukin 13 monoclonal antibody, in active UC: efficacy and safety from a phase IIa randomised multicentre study | Q44799322 | ||
| Inflammatory gene expression by human colonic smooth muscle cells | Q44875003 | ||
| Transforming growth factor beta 1 selectively augments collagen synthesis by human intestinal smooth muscle cells | Q44985170 | ||
| Interleukin 1 beta down-regulates collagen and augments collagenase expression in human intestinal smooth muscle cells | Q45095597 | ||
| P304 | page(s) | 126 | |
| P577 | publication date | 2017-08-07 | |
| P1433 | published in | Frontiers in Medicine | Q27726181 |
| P1476 | title | The Role of Cytokines in the Fibrotic Responses in Crohn's Disease | |
| P478 | volume | 4 |
| Q55512054 | A Noninvasive Method to Assess Mucosal Healing in Patients* With Crohn’s Disease. |
| Q91904006 | Anti-IL-13Rα2 therapy promotes recovery in a murine model of inflammatory bowel disease |
| Q64079601 | Coinfection Attenuates Murine -Induced Crohn's-Like Ileitis by Preserving the Epithelial Barrier and Downregulating the Inflammatory Response |
| Q92447462 | Dissecting the Heterogeneity in T-Cell Mediated Inflammation in IBD |
| Q96302616 | Dose-dependent pro- or anti-fibrotic responses of endometriotic stromal cells to interleukin-1β and tumor necrosis factor α |
| Q102152292 | Mycobacterial Hsp65 antigen delivered by invasive Lactococcus lactis reduces intestinal inflammation and fibrosis in TNBS-induced chronic colitis model |
| Q60920821 | Oversecretion and Overexpression of Nicotinamide Phosphoribosyltransferase/Pre-B Colony-Enhancing Factor/Visfatin in Inflammatory Bowel Disease Reflects the Disease Activity, Severity of Inflammatory Response and Hypoxia |
| Q93075393 | Pathogenesis of fibrostenosing Crohn's disease |
| Q49972870 | SHIP negatively regulates type II immune responses in mast cells and macrophages |
Search more.